OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

Summary

The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.

Eligibility

Inclusion Criteria:

* Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube) and carcinosarcoma patients with a suspected FIGO Stage III and IV
* No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis
* Envisaged surgical candidate for interval debulking after 2 cycles of treatment
* Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures
* ECOG 0-2
* Written informed consent according to national legal and regulatory requirements prior to any project specific procedures

Exclusion Criteria:

* Elevated liver enzymes (double of normal range: ASAT \> 68 U/l; ALAT \> 82 U/l; GGT \> 80 U/l)
* Elevated creatinine (double of normal range: \>120 mmol/l))
* ECOG ≥3
* Pregnant or lactating women
* Any other malignancy within the last 5 years which has an impact on the prognosis of the patient
* Inability to swallow tablets
* Concurrent participation in another clinical trial on the same indication
* Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the sponsor-project leader may interfere with the project or affect patient compliance

Conditions5

Browse More Trials